Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Company Overview - Cogent Biosciences is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined diseases, leveraging precision medicine to address unmet medical needs in oncology and rare disease markets [5] - The company has a lead product candidate, CGT9486, aimed at treating systemic mastocytosis and advanced gastrointestinal stromal tumors, and operates through a biotechnology R&D model [8] Financial Performance - As of February 17, 2026, Cogent Biosciences had a market capitalization of $5.6 billion and a net income of -$328.94 million (TTM) [4] - The company's stock price was $34.40, reflecting a 372% increase over the past year, significantly outperforming the S&P 500's 16% gain during the same period [7] Recent Developments - Boone Capital Management sold its entire stake of 945,042 shares in Cogent Biosciences, liquidating a position valued at $13.57 million [1][2] - Despite the liquidation, Cogent is reported to be in a strong position with approximately $900 million in cash and a clear path toward potential commercialization, including multiple NDA filings [9] Market Position and Strategy - Cogent's strategy includes advancing innovative kinase inhibitors and forming strategic collaborations, such as its partnership with Plexxikon Inc. for bezuclastinib [5][8] - The company targets patients with rare genetic mutations, particularly those affected by KIT-driven cancers and systemic mastocytosis, serving the global biopharmaceutical and healthcare markets [8]